Luke O'Neill
👤 SpeakerAppearances Over Time
Podcast Appearances
So, freely available.
But that will be used immediately, watch, because it's freely available.
And what's the other development?
This is more exciting because this is more experimental.
GSK, the drug company, give them credit.
A drug called Mores.
Now, there's a mouthful for you.
They developed this drug called Mores and they got a 62% response rate, which meant 62% of people responded really well.
Their tumours shrank and were eliminated.
Yeah.
With ovarian cancer.
Eliminate.
Yeah, and some of these people with this drug, and it's a very powerful drug.
In ovarian cancer, the cancer cells overexpress a thing called B7H4 on their surface, like a flag goes up on the cancer cell.
Yeah.
This was a drug, an antibody that could lock onto that.
And it carried a poison with it.
They're called antibody drug conjugates.
So you attach a nasty chemical to an antibody that targets this thing, B7H4, and the chemical kills the cell.
There's been a few ideas around this already in the past.